Immunomic Therapeutics Initiates Phase I Trial of ITI-1001 for Newly Diagnosed Glioblastoma
Immunomic Therapeutics has launched Phase I trial to assess ITI-1001 in patients with newly diagnosed glioblastoma.
Asset / Drug
Drug and asset intelligence for ITI-1001 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.